Content about STOCKHOLM

August 12, 2013

Moberg Pharma AB announced its U.S. launch of Kerasal NeuroCream, an over-the-counter pain relieving foot cream.

STOCKHOLM, Sweden — Moberg Pharma AB today announced its U.S. launch of Kerasal NeuroCream, an over-the-counter pain relieving foot cream. This new product will be sold in over 3,800 Walmart stores and in CVS, Walgreens, and Rite Aid drug stores starting late August.

January 10, 2011

Boots Pharmaceutical Enterprises, the partnership between the U.K. pharmacy chain Boots and local operator Pharmaceutical Enterprises, in the next two months is expected to open the first of 100 pharmacies across Sweden, according to a report in The Local, an English-language Swedish newspaper.

STOCKHOLM, Sweden — Boots Pharmaceutical Enterprises, the partnership between the U.K. pharmacy chain Boots and local operator Pharmaceutical Enterprises, in the next two months is expected to open the first of 100 pharmacies across Sweden, according to a report in The Local, an English-language Swedish newspaper.

”We are busy recruiting candidates and finding premises here in Sweden,” Sverker Littorin, Pharmaceutical Enterprises chairman told the newspaper. “Everything is on track, even though it is several months later than we had hoped.”

October 21, 2010

Diamyd Medical will split its business into separate divisions for pain relief and diabetes, the...

STOCKHOLM Diamyd Medical will split its business into separate divisions for pain relief and diabetes, the drug maker said Friday.

 

The Swedish company said its diabetes business would consist mostly of the investigational antigen-based drug Diamyd, for Type 1 diabetes, while the pain business would comprise of development projects using its nerve-targeting drug delivery system platform to administer drugs directly to the nervous system to treat pain.

 

 

October 14, 2010

The Food and Drug Administration has given orphan drug designation to a treatment for a...

STOCKHOLM The Food and Drug Administration has given orphan drug designation to a treatment for a rare kidney disease under mid-stage clinical development by privately owned Swedish drug maker PharmaLink, the company said.

 

The FDA granted the designation to Nefecon (PL-56), a treatment for IgA nephropathy, also known as Berger’s disease, a disorder that leads to end-stage kidney disease. The FDA gives orphan drug designation to incentivize development of treatments for rare and serious disorders.

 

 

September 23, 2010

An investigational diabetes drug works as well as a generic already on the market, according...

STOCKHOLM An investigational diabetes drug works as well as a generic already on the market, according to results of a late-stage clinical trial announced Friday by AstraZeneca and Bristol-Myers Squibb.

 

September 19, 2010

An injected insulin made by French drug maker Sanofi-Aventis provided further reduction of blood sugar...

PARIS An injected insulin made by French drug maker Sanofi-Aventis provided further reduction of blood sugar in patients with Type 2 diabetes when added to oral diabetes drugs, according to a study presented at a medical conference in Sweden.

September 19, 2010

An investigational treatment made by French drug maker Sanofi-Aventis showed “significant” improvement in blood-glucose control...

PARIS An investigational treatment made by French drug maker Sanofi-Aventis showed “significant” improvement in blood-glucose control in patients with diabetes, according to results of a late-stage clinical trial presented at a scientific meeting.

August 29, 2010

Meda on Monday announced an agreement to acquire the specialty pharmaceutical company Alaven in a...

STOCKHOLM Meda on Monday announced an agreement to acquire the specialty pharmaceutical company Alaven in a move that will “significantly enhance Meda’s marketing capabilities in the United States and expand the therapeutic focus to include both gastroenterology and women’s health — areas that Meda already operates in outside of the United States,” the company stated.

 

Meda also identified Alaven’s over-the-counter platform, which accounts for approximately 25% of Alaven’s sales, as an attractive element to the deal.

August 16, 2010

A new study now available online in the journal Pediatrics supported earlier clinical research about...

STOCKHOLM A new study now available online in the journal Pediatrics supported earlier clinical research about the benefits of a specific probiotic strain on colic symptoms in infants, BioGaia recently announced.

 

In the new study, infants supplemented with Lactobacillus reuteri Protectis showed a significant reduction in crying time. After one week of supplementation, the reduction in crying time was 74% in the L. reuteri Protectis group, compared with 38% in the placebo group.